Amgen Inc. finds, creates, produces, and distributes human medicines globally. The main products of the company consist of Enbrel for treating plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for treating adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers related to Behçet’s disease; Prolia for treating postmenopausal women with osteoporosis; XGEVA is used to prevent skeletal-related events; Repatha lowers the chances of heart attack, stroke, and the need for heart surgery; Nplate is used to treat people with immune thrombocytopenia.
KYPROLIS is used to help patients with relapsed or refractory multiple myeloma; Aranesp is used to address a lower-than-normal count of red blood cells and anaemia; EVENITY is prescribed for managing osteoporosis in postmenopausal individuals, both men and women; Vectibix is administered to patients with wild-type RAS metastatic colorectal cancer; BLINCYTO is indicated for patients with acute lymphoblastic leukaemia; TEPEZZA is prescribed for treating thyroid eye disease; and KRYSTEXXA is used for chronic refractory gout treatment.
It also sells other items such as Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI. The organisation caters to healthcare providers such as doctors or their clinics, dialysis centres, hospitals, and pharmacies. It sells its products through pharmaceutical wholesale wholesalers, as well as directly to consumers.
The company has partnerships with AstraZeneca plc to work together on TEZSPIRE; Novartis Pharma AG for the development and sale of Aimovig; UCB to develop and sell EVENITY; Kyowa Kirin Co., Ltd. for the development and sale of rocatinlimab; and BeiGene, Ltd. to expand and develop oncology products.
Amgen Inc. was established in 1980 and is based in Thousand Oaks, California.
Here is a recent news on Amgen inc.